Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis ...

Kymera Therapeutics Inc (KYMR) extends cash runway into 2028, bolstered by key partnerships with Gilead and Sanofi, despite ...

Q2 2025 Management View CEO Nello Mainolfi outlined major progress in 2025, declaring “the updates we've shared in the first ...

Q2 2025 Earnings Call Transcript August 11, 2025 Kymera Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera ...

Gilead and Kymera said CDK2-directed MGDs are a new type of drug designed to remove CDK2, rather than just inhibiting its function, adding that their collaboration has broad oncology treatment ...

Kymera Therapeutics Inc. found itself juggling partnerships by bringing one on board while going to the development bench in another. Kymera and Gilead Sciences Inc. will collaborate on a molecular ...

Kymera Therapeutics may have signed a $750 million deal with Gilead, but the Watertown biotech also suffered a setback in its partnership with Sanofi and announced a $250 million secondary offering.

CDK2-directed MGDs are a new type of drug designed to remove CDK2 – a key contributor in tumor growth – rather than just inhibiting its function. Traditional inhibitors of CDK2 prevent it from ...

Gilead Sciences partners with Kymera Therapeutics in a $750 million deal to develop molecular glue degraders for breast cancer treatment.

Capricor, Gilead, Kymera, Praxis among Oppenheimer’s top biotech picks for 2025 December 19, 2024 — 06:15 am EST Written by TheFly for TipRanks -> ...